<DOC>
	<DOCNO>NCT00870181</DOCNO>
	<brief_summary>Malignant glioma common primary brain tumor adult , prognosis patient tumor remain poor despite advance diagnosis standard therapy surgery , radiation therapy , chemotherapy . The advantage ADV-TK gene therapy highlight efficacy safety glioma patient . This clinical trial conduct assess anti-tumor efficacy safety intraarterial cerebral infusion replication-deficient adenovirus mutant ADV-TK , combination systemic intravenous GCV administration patient recurrent high-grade glioma .</brief_summary>
	<brief_title>ADV-TK Improves Outcome Recurrent High-Grade Glioma</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Glioma</mesh_term>
	<criteria>Histologically confirm WHO grade 3 4 malignant glioma Diagnosed recurrence progression clinical radiological evidence Fit intraarterial infusion intravenous chemotherapy Adequate hepatic , renal , hematologic function . Legal age ≥18 year Life expectancy ≥12 week Eastern Cooperative Oncology Group performance ( ECOG ) ≥2 Chemotherapy completion ≥4 week prior recovery drug induce toxicity . Active pregnancy Prior gene therapy Second primary tumor Gravidity , lactation , hypersensitivity antiviral drug , immunologic deficit , active uncontrolled infection Requiring treatment warfarin anticoagulant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>